Importance:
Allergic diseases are prevalent in childhood. Early exposure to medications that can alter the microbiome, including acid-suppressive medications and antibiotics, may influence the likelihood of allergy.
Objective:
To determine whether there is an association between the use of acid-suppressive medications or antibiotics in the first 6 months of infancy and development of allergic diseases in early childhood.
Design, Setting, And Participants:
A retrospective cohort study was conducted in 792 130 children who were Department of Defense TRICARE beneficiaries with a birth medical record in the Military Health System database between October 1, 2001, and September 30, 2013, with continued enrollment from within 35 days of birth until at least age 1 year. Children who had an initial birth stay of greater than 7 days or were diagnosed with any of the outcome allergic conditions within the first 6 months of life were excluded from the study. Data analysis was performed from April 15, 2015, to January 4, 2018.
Exposures:
Exposures were defined as having any dispensed prescription for a histamine-2 receptor antagonist (H2RA), proton pump inhibitor (PPI), or antibiotic.
Main Outcomes And Measures:
The main outcome was allergic disease, defined as the presence of food allergy, anaphylaxis, asthma, atopic dermatitis, allergic rhinitis, allergic conjunctivitis, urticaria, contact dermatitis, medication allergy, or other allergy.
Results:
Of 792 130 children (395 215 [49.9%] girls) included for analysis, 60 209 (7.6%) were prescribed an H2RA, 13 687 (1.7%) were prescribed a PPI, and 131 708 (16.6%) were prescribed an antibiotic during the first 6 months of life. Data for each child were available for a median of 4.6 years. Adjusted hazard ratios (aHRs) in children prescribed H2RAs and PPIs, respectively, were 2.18 (95% CI, 2.04-2.33) and 2.59 (95% CI, 2.25-3.00) for food allergy, 1.70 (95% CI, 1.60-1.80) and 1.84 (95% CI, 1.56-2.17) for medication allergy, 1.51 (95% CI, 1.38-1.66) and 1.45 (95% CI, 1.22-1.73) for anaphylaxis, 1.50 (95% CI, 1.46-1.54) and 1.44 (95% CI, 1.36-1.52) for allergic rhinitis, and 1.25 (95% CI, 1.21-1.29) and 1.41 (95% CI, 1.31-1.52) for asthma. The aHRs after antibiotic prescription in the first 6 months of life were 2.09 (95% CI, 2.05-2.13) for asthma, 1.75 (95% CI, 1.72-1.78) for allergic rhinitis, 1.51 (95% CI, 1.38-1.66) for anaphylaxis, and 1.42 (95% CI, 1.34-1.50) for allergic conjunctivitis.
Conclusions And Relevance:
This study found associations between the use of acid-suppressive medications and antibiotics during the first 6 months of infancy and subsequent development of allergic disease. Acid-suppressive medications and antibiotics should be used during infancy only in situations of clear clinical benefit.
Citing Articles
Why think twice before prescribing proton pump inhibitors.
Lemmens A, Huysentruyt K, Vandenplas Y
Eur J Pediatr. 2025; 184(3):227.
PMID: 40042553
DOI: 10.1007/s00431-025-06058-z.
Innovative Therapeutic Strategies for Asthma: The Role of Gut Microbiome in Airway Immunity.
Liu Y, Dai J, Zhou G, Chen R, Bai C, Shi F
J Asthma Allergy. 2025; 18:257-267.
PMID: 39996012
PMC: 11849427.
DOI: 10.2147/JAA.S504571.
Fetal and Early-Life Antibiotics and Risk of Pediatric Inflammatory Bowel Disease: A Population-Based Nationwide Register Study.
Andersen S, Hestetun S, Bernklev T, Perminow G, Stordal K
J Pediatr Clin Pract. 2025; 12:200096.
PMID: 39949419
PMC: 11824603.
DOI: 10.1016/j.jpedcp.2024.200096.
Risk factors of allergic rhinitis and its prevention strategies.
Chen R, An W, Liu X, Yan J, Huang Y, Zhang J
Front Allergy. 2024; 5:1509552.
PMID: 39665077
PMC: 11632107.
DOI: 10.3389/falgy.2024.1509552.
Disease Burden and Spectrum of Symptoms that Impact Quality of Life in Pediatric Patients with Eosinophilic Esophagitis.
Chehade M, Hiremath G, Zevit N, Oliva S, Pela T, Khodzhayev A
Gastro Hep Adv. 2024; 3(8):1054-1068.
PMID: 39529644
PMC: 11550740.
DOI: 10.1016/j.gastha.2024.08.009.
The Influence of Premature Birth on the Development of Pulmonary Diseases: Focus on the Microbiome.
Wolska M, Wypych T, Rodriguez-Viso P
Metabolites. 2024; 14(7).
PMID: 39057705
PMC: 11279213.
DOI: 10.3390/metabo14070382.
Insights into the clinical, immunologic, and genetic underpinnings of food allergy.
Frischmeyer-Guerrerio P, Young F, Aktas O, Haque T
Immunol Rev. 2024; 326(1):162-172.
PMID: 39034662
PMC: 11436304.
DOI: 10.1111/imr.13371.
Probiotics and Antibiotic-Induced Microbial Aberrations in Children: A Secondary Analysis of a Randomized Clinical Trial.
Dierikx T, Malinowska A, Lukasik J, Besseling-van der Vaart I, Belzer C, Szajewska H
JAMA Netw Open. 2024; 7(7):e2418129.
PMID: 38967929
PMC: 11227081.
DOI: 10.1001/jamanetworkopen.2024.18129.
Gut-lung axis and asthma: A historical review on mechanism and future perspective.
Song X, Liang J, Lin S, Xie Y, Ke C, Ao D
Clin Transl Allergy. 2024; 14(5):e12356.
PMID: 38687096
PMC: 11060082.
DOI: 10.1002/clt2.12356.
Safety of Proton Pump Inhibitors in Pediatric Population: A Systematic Review.
Alla D, Shah D, Seepana M, Salian R, Alla S, Krishna Mohanan M
Glob Pediatr Health. 2024; 11:2333794X241248967.
PMID: 38685999
PMC: 11057350.
DOI: 10.1177/2333794X241248967.
Antibiotic Treatment for Well-Appearing Infants Born at ≥35 Weeks' Gestation to Mothers with Chorioamnionitis Before and After Implementation of Neonatal Early-Onset Sepsis Calculator.
Bajracharya S, Prazad P, Bennett C, Asado N
J Patient Cent Res Rev. 2024; 11(1):29-35.
PMID: 38596346
PMC: 11000701.
DOI: 10.17294/2330-0698.2005.
Proton Pump Inhibitors in Pediatric Gastroesophageal Reflux Disease: A Systematic Review of Randomized Controlled Trials.
Fernandez-Gonzalez S, Moreno-Alvarez A, Solar-Boga A
Children (Basel). 2024; 11(3).
PMID: 38539331
PMC: 10969042.
DOI: 10.3390/children11030296.
Acid-suppressive medication and incidence of chronic childhood immune-mediated diseases: A scoping review.
Madej J, Atanassova T, McGuire S, Cohen B, Weidner M, Zhang Y
Pediatr Allergy Immunol. 2023; 34(11):e14042.
PMID: 38010007
PMC: 10683867.
DOI: 10.1111/pai.14042.
Fruit Pouch Consumption Does Not Associate with Early Manifestations of Allergic Disease.
Fredriksson E, Boden S, Domellof M, West C
Nutrients. 2023; 15(20).
PMID: 37892394
PMC: 10609626.
DOI: 10.3390/nu15204318.
Long-term dysbiosis and fluctuations of gut microbiome in antibiotic treated preterm infants.
Cetinbas M, Thai J, Filatava E, Gregory K, Sadreyev R
iScience. 2023; 26(10):107995.
PMID: 37829203
PMC: 10565780.
DOI: 10.1016/j.isci.2023.107995.
Kaiser Permanente early-onset sepsis calculator as a safe tool for reducing antibiotic use among chorioamnionitis-exposed term neonates: Qatar experience.
Vellamgot A, Salameh K, AlBedaywi R, Alhoyed S, Habboub L, Abdellatif W
BMJ Open Qual. 2023; 12(4).
PMID: 37827729
PMC: 10582875.
DOI: 10.1136/bmjoq-2023-002459.
Maternal constipation is associated with allergic rhinitis in the offspring: A nationwide retrospective cohort study.
Lee M, Wu M, Wang Y, Cheng-Chung Wei J
PLoS One. 2023; 18(10):e0292594.
PMID: 37797074
PMC: 10553815.
DOI: 10.1371/journal.pone.0292594.
Markers of platelet activation foR identification of late onset sEpsis in infaNTs: PARENT study protocol.
OReilly D, Murphy C, Moore C, Ainle F, Gormley I, Morrell C
Pediatr Res. 2023; 95(3):852-856.
PMID: 37758864
DOI: 10.1038/s41390-023-02812-x.
[Establishment of a nomogram model for predicting the risk of early-onset sepsis in very preterm infants].
Wei X, Zhang J, Hao Q, DU Y, Cheng X
Zhongguo Dang Dai Er Ke Za Zhi. 2023; 25(9):915-922.
PMID: 37718396
PMC: 10511222.
DOI: 10.7499/j.issn.1008-8830.2302002.
Environmental Risk Factors, Protective Factors, and Biomarkers for Allergic Rhinitis: A Systematic Umbrella Review of the Evidence.
Xu X, Liu X, Li J, Deng X, Dai T, Ji Q
Clin Rev Allergy Immunol. 2023; 65(2):188-205.
PMID: 37490237
PMC: 10567804.
DOI: 10.1007/s12016-023-08964-2.